KEKarl Engelhard

Karl Engelhard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karl Engelhard has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions

    by Katja Bogner, Karl Engelhard, Wolfgang Wuest, Sajad Hamel

    Purpose To evaluate the validity of PI-RADS categories 1 and 2 version 2.1 (V2.1) as predictors of the absence of carcinoma and to reevaluate lesions that were analysed as suspicious prior to PI-RADS or according to PI-RADS versions 1 and 2 and classified as PI-RADS 1 or 2 in V2.1. Methods Retrospective evaluation of 1170 multiparametric MRIs performed at one academic teaching hospital (2012–2019). Study cohort comprised 188 men that achieved PI-RADS scores 1 or 2 (V2.1) and underwent systematic and targeted biopsy, split into one group with suspect findings in the original reports that were created prior to PI-RADS or with version 1 and 2, and another group with unremarkable reports. Differences in presence of prostate cancer and PSA density were assessed by Chi-square and Fisher’s exact test, and the negative predictive value (NPV) for both groups was conducted. Results The NPV for clinically significant carcinoma (csCa) was 89.1% for 55 men with suspect findings in the original report and 93.2% for 133 men with negative MRI. There was no difference between the groups regarding the detection of csCa (p = 0.103). PSA density was significantly higher in the group with suspect original reports (p = 0.015). Conclusion A PI-RADS score 1 or 2 appears less likely to miss existing prostate cancer, although a small amount of csCa can be overlooked. In case of clinical suspicion or elevated PSA density and PI-RADS score 1 or 2, an individual decision has to be taken if biopsy is necessary or if monitoring is sufficient. Graphical abstract


  • Open Access

    PI-Rads Scores and MRI-Targeted Prostate Biopsy

    by Karl Engelhard

    International journal of nephrology is an Open Access, peer-reviewed international journal that provides current information of research, development and treatment aspects that are involved in the fields of urology and nephrology. Urology is the branch of medicine

    • 1 August 2016
      • Vol. 36  (8) , 4279-83

    The Value of Endorectal Magnetic Resonance Imaging of the Prostate in Improving the Detection of Anterior Prostate Cancer.

    by Vahudin Zugor, Reinhard Kühn, Karl Engelhard, Sandor Poth, Marija Maja Bernat, Daniel Porres, Apostolos P Labanaris

    The diagnosis of anterior prostate cancer (APC) is troublesome due to its anatomical location. Patients with an APC often require multiple sets of biopsies until diagnosis is made. The objective of this study is to examine if endorectal magnetic resonance imaging (e-MRI) of the prostate could improve the detection of APC. A retrospective review of 412 patients records with a clinical suspicion of prostate cancer (PCa) (prostate-specific antigen (PSA) levels >4 ng/ml or a suspicious finding on digital rectal examination (DRE)) who underwent conventional e-MRI (e-cMRI) and functional e-MRI (e-fMRI) of the prostate and subsequent prostate biopsy from April 2004 to July 2010 was conducted. All patients had a history of at least one prior negative set of prostate biopsy. Sixty-five percent (N=268) of patients' images were considered suspicious for PCa of which 53 (12.8%) cases were considered to be suspicious for APC (defined as the presence of PCa anterior to the urethra). All patients underwent an 18-core transrectal ultrasonography (TRUS)-guided biopsy of the peripheral zone and an additional 3-core TRUS-targeted biopsy anterior to the urethra. The median age and median PSA levels of the patients was 68.9 (range=56-72) years and 12.7 ng/ml (range=6.4-21.3), respectively. DRE was only positive in 6 patients (11.4%). The overall PCa detection rate was 90.5%. APC was detected through the targeted cores in 48 patients (90.5%). Seven patients (13.2%) exhibited a PCa of the peripheral zone as well. e-MRI-positive predictive value was 90.5%. e-MRI of the prostate has a high predictive value in detecting APC. Patients with a constant increase of PSA levels, negative DRE findings and prior negative sets of prostate biopsy are ideal candidates for e-MRI of the prostate and subsequent TRUS-targeted biopsies of possible suspicious anterior gland sites.


  • Impact of magnetic resonance imaging-guided prostate biopsy in the supine position on the detection of significant prostate cancer in an inhomogeneous patient cohort

    by Karl Engelhard, Reinhart Kühn, Artur Osten, Katja Bogner, Anton Dworak, Lars Lübke, Florian Schneider

    Objective: The aim of this study was to determine the tumour detection rate of magnetic resonance-guided biopsy (MRGB) in the supine position for significant prostate cancer in an inhomogeneous patient cohort. Materials and methods: Thirty-two consecutive patients with a total prostate-specific antigen > 4 ng/ml and/or a tumour-suspicious palpable lesion upon digital rectal examination and a cancer-suspicious region in multiparametric magnetic resonance imaging (MRI) underwent MRGB in a standard 1.5 T magnet. Diagnostic MRI was performed in 20 patients at the authors’ institute and 12 men at another location. Eight patients were investigated at 3 T and 24 at 1.5 T. Twenty men had prior negative biopsies and 12 were biopsy naïve. All biopsies were performed in the supine position using a table-mounted device and an 18 G biopsy gun. Results: The overall tumour detection rate was 53% (17/32). Two cores (median; range 1–4) were extracted. Clinically significant cancers were found in 94% (16/17). None of the patients showed any postbiopsy complications. The prostate volumes of patients with cancer were significantly lower (39.3 ml) than those of men without cancer (49.7 ml). No significant differences were found between the numbers of tumour-positive and tumour-negative collected cores. In a median follow-up of 14 months, no cancer was detected in the negative biopsy group. Conclusion: MRGB in the supine position can be a valuable tool to detect significant prostate cancer, even in a patient cohort with different prebiopsy pathways. The biopsy method could be a reasonable alternative to MRGB in the prone position.


  • How good is post-biopsy multiparametric magnetic resonance imaging in detecting and characterising the index lesion of localised prostate cancer?

    by Karl Engelhard, Apostolos P. Labanaris, Katja Bogner, Lars Lübke, Otto Dworak, Reinhard Kühn

    Objective. The aim of this study was to evaluate the accuracy of multiparametric endorectal magnetic resonance imaging (mp-MRI) in detecting and characterising the largest tumour lesion, which is defined as the index tumour of prostate cancer. Material and methods. A total of 55 patients with proven histological prostate cancer underwent post-biopsy MRI at 1.5 T and subsequent radical prostatectomy. The maximum tumour diameter (MTD) of the index lesion was determined independently by MRI and histopathology in a prospective manner. The detection rate of the index lesion, the MTD and volume by pathology, and the pathological tumour (pT) stage were correlated with the MTD by MRI using Pearson's correlation. Results. Pathohistology revealed 158 cancer foci. MRI detected 55 foci. The sensitivity, specificity, accuracy, and negative and positive predictive values of mp-MRI for index lesion detection were 89%, 100%, 90%, 44% and 100%, respectively. Three positive correlations were found: one between the MTD of the index lesion by MRI and the MTD by pathology (Pearson coefficient = 0.890, p < 0.01), a second between the MTD by MRI and the index tumour volume at pathology (Pearson coefficient = 0.786, p < 0.01), and a third between the MTD and the pT stage (Pearson coefficient = 0.678, p < 0.01). Conclusion: mp-MRI can accurately detect the index lesion and estimate the TVP of localised prostate cancer.


  • Vorgehen bei MRT-gesteuerten Biopsien der Prostata

    by K Engelhard, D Engehausen

    Die TRUS-gesteuerte Mehrfachbiopsie der Prostata bildet den Goldstandard bei Paienten mit erhötem PSA Wert (>4ng/ml) in der Urologie. Die multiparametrische MRT-Diagnostik bei 1,5- und 3Tesla zeigt unter Verwendung einer Endorektalspule hohe Treffsicherheiten in der Detektion und Lokalisation des Tumors und vermag in Studien für den Patienten behandlungsbedürftigen Malignome darzustellen. Die MRT-gesteuerte Stanzbiopsie gestattet die Biopsie verdächtiger Herdbildungen unter direkter MRT-Sichtkontrolle. Dies betrifft insbesondere Patienten mit wiederholt Tumor negativen Stanzbiopsien bei weiterbestehender PSA Erhöhung. Die Durchführung und angewandte Techniken variieren in den verschiedenen Zentren. Manuelle Biopsien werden in Bauch- und Rückenlage in geschloßenen Magneten durchgeführt. Es werden 3 verschieden Techniken vorgestellt mit Erläuterung von Vor-und Nachteilen der jeweiligen Anwendungsart und Biopsievorrichtung. Die Vorbereitung, der Ablauf und die Ergebnisse der Behandlung werden dargestellt und die Handhabung der Biopsieeinrichtung einer Technik in einzelnen Schritten fallbasiert vorgestellt. Auf Probleme bei der praktischen Durchführung wie anatomische Besonderheiten, Drüsengröße und Bewegungsartefakte wird eingegangen. Indikationen, Qualitätssicherung, Sequenztechniken, Software und Kosten der Systeme werden erläutert. Lernziele: Wissen bezüglich der Indikation für eine MRT-gesteuerte Stanzbiopsie. Kenntnisse bezüglich angebotener Biopsieeinrichtiungen in klinischen Studien und mit CE-Zertifizierung. Erlernen des Ablaufs einer praktischen Durchführung eines Systems unter Zuhilfenahme der Bildtechniken, angebotener Software und der Biopsieeinrichtung. Einschätzung des Stellenwerts und der Validität der Methode und Veständniss bezüglich der Patientenselektion. Annahme des Angebots weiterführender Literatur. Die Demonstration einer Biopsieeinrichtung anhand eines Modells im Vortragsraum am Ende des Kurses wird angestrebt. Korrespondierender Autor: Engelhard K Krankenhaus Martha-Maria, Diagnostische Radiologie, Stadenstr. 58, 90491 Nürnberg E-Mail: karl.engelhard@martha-maria.de

    • 14 March 2007
      • Vol. 27, 687-93

    MRI spectroscopy in screening of prostate cancer.

    by Katja Goeb, Dirk G Engehausen, F Steffen Krause, Hans-Peter Hollenbach, Gerald Niedobitek, Maike Buettner, Phroso Frangou, Karl Engelhard

    The purpose of this study was to evaluate the suitability of MR Spectroscopy in screening for prostate cancer in comparison to T2-weighted MR imaging. Forty-six patients with biopsy confirmed prostate cancer underwent combined endorectal-body-phased-array MRI at 1.5T (Tesla). Twelve patients were additionally examined with 3D-spectroscopy sequence. The results of the spectroscopy were compared with the findings of T2-weighted MR imaging and the histological examination of radical prostatectomy specimens. With 3D-spectroscopy, a choline+creatine/citrate-ratio of 0.45 for healthy tissue and a ratio of 1.90 for tumor tissue were found and a significant difference between the groups was demonstrated. In 6 cases diagnosis of tumor localization was improved with spectroscopy in comparison with T2-weighted imaging alone. 3D-spectroscopy is a suitable technique for improving MR imaging of prostate cancer. This method can improve the diagnostic accuracy of T2-weighted imaging alone. At present, 3D-CSI spectroscopy alone can not be recommended with sufficient validity.